{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T16:11:33Z","timestamp":1787501493347,"version":"build-2736575974"},"reference-count":16,"publisher":"BMJ","issue":"3","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Case Rep"],"accepted":{"date-parts":[[2022,2,10]]},"published-print":{"date-parts":[[2022,3]]},"abstract":"<jats:p>A man in his 70s with rheumatoid arthritis presented with seizures and coma and was transferred to our emergency department. Two months prior to admission, he started to take tofacitinib 10\u2009mg\/day. On admission, we noted a rash with a blister on the forehead, and herpes zoster was diagnosed. Cerebrospinal fluid examination suggested meningitis. An MRI of the brain showed no abnormality. Based on these findings, he was suspected with herpes zoster meningitis. We discontinued tofacitinib and treated the patient with intravenous acyclovir for 2\u2009weeks. He regained complete consciousness, but right forehead skin lesion, severe vision loss in the right eye and right facial nerve paralysis remained as sequelae. Six weeks after admission, we restarted tofacitinib with oral valaciclovir as antiviral prophylaxis. Two years after admission, we administered Shingrix, an adjuvant recombinant vaccine for herpes zoster, and discontinued oral valaciclovir.<\/jats:p>","DOI":"10.1136\/bcr-2021-247276","type":"journal-article","created":{"date-parts":[[2022,3,2]],"date-time":"2022-03-02T11:06:11Z","timestamp":1646219171000},"page":"e247276","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":3,"title":["Herpes zoster meningitis in a rheumatoid arthritis patient treated with tofacitinib"],"prefix":"10.1136","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1130-538X","authenticated-orcid":false,"given":"Yoshihiro","family":"Nakamura","sequence":"first","affiliation":[{"name":"Department of Rheumatology, Chubu Rosai Hospital, Nagoya, Aichi, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daiyu","family":"Honda","sequence":"additional","affiliation":[{"name":"Department of Neurology, Nagoya Daiichi Sekijuji Byoin, Nagoya, Aichi, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3744-3537","authenticated-orcid":false,"given":"Naoho","family":"Takizawa","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Chubu Rosai Hospital, Nagoya, Aichi, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshiro","family":"Fujita","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Chubu Rosai Hospital, Nagoya, Aichi, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2022,3,2]]},"reference":[{"key":"2025082723521313000_15.3.e247276.1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2020-218398"},{"key":"2025082723521313000_15.3.e247276.2","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2019-216655"},{"key":"2025082723521313000_15.3.e247276.3","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1002\/art.41752","article-title":"2021 American College of rheumatology guideline for the treatment of rheumatoid arthritis","volume":"73","author":"Fraenkel","year":"2021","journal-title":"Arthritis Rheumatol"},{"key":"2025082723521313000_15.3.e247276.4","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1056\/NEJMoa2031994","article-title":"Baricitinib plus Remdesivir for hospitalized adults with Covid-19","volume":"384","author":"Kalil","year":"2021","journal-title":"N Engl J Med"},{"key":"2025082723521313000_15.3.e247276.5","doi-asserted-by":"crossref","DOI":"10.1007\/s11926-020-00931-6","article-title":"Jak inhibitors: what is new?","volume":"22","author":"Reddy","year":"2020","journal-title":"Curr Rheumatol Rep"},{"key":"2025082723521313000_15.3.e247276.6","doi-asserted-by":"crossref","first-page":"2675","DOI":"10.1002\/art.38745","article-title":"Herpes zoster and tofacitinib therapy in patients with rheumatoid arthritis","volume":"66","author":"Winthrop","year":"2014","journal-title":"Arthritis Rheumatol"},{"key":"2025082723521313000_15.3.e247276.7","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1093\/rheumatology\/kez087","article-title":"A systematic review and meta-analysis of infection risk with small molecule JAK inhibitors in rheumatoid arthritis","volume":"58","author":"Bechman","year":"2019","journal-title":"Rheumatology"},{"key":"2025082723521313000_15.3.e247276.8","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2019-215882"},{"key":"2025082723521313000_15.3.e247276.9","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2007.08.046"},{"key":"2025082723521313000_15.3.e247276.10","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1097\/QCO.0000000000000647","article-title":"Central nervous system infections produced by varicella zoster virus","volume":"33","author":"Nagel","year":"2020","journal-title":"Curr Opin Infect Dis"},{"key":"2025082723521313000_15.3.e247276.11","doi-asserted-by":"crossref","first-page":"E74","DOI":"10.1002\/ajh.24688","article-title":"Varicella-Zoster virus meningoencephalitis in a patient treated with ruxolitinib","volume":"92","author":"Eyal","year":"2017","journal-title":"Am J Hematol"},{"key":"2025082723521313000_15.3.e247276.12","doi-asserted-by":"crossref","first-page":"2258","DOI":"10.1093\/ibd\/izy131","article-title":"Herpes zoster infection in patients with ulcerative colitis receiving tofacitinib","volume":"24","author":"Winthrop","year":"2018","journal-title":"Inflamm Bowel Dis"},{"key":"2025082723521313000_15.3.e247276.13","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1080\/03009742.2020.1800082","article-title":"Varicella zoster virus myelitis in a patient with rheumatoid arthritis treated by tofacitinib","volume":"50","author":"Itamiya","year":"2021","journal-title":"Scand J Rheumatol"},{"key":"2025082723521313000_15.3.e247276.14","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1002\/acr2.11150","article-title":"Safety of the zoster vaccine recombinant adjuvanted in rheumatoid arthritis and other systemic rheumatic disease patients: a single center's experience with 400 patients","volume":"2","author":"Stevens","year":"2020","journal-title":"ACR Open Rheumatol"},{"key":"2025082723521313000_15.3.e247276.15","doi-asserted-by":"crossref","first-page":"5149","DOI":"10.1093\/rheumatology\/keab139","article-title":"Safety of recombinant zoster vaccine: a retrospective study of 622 rheumatology patients","volume":"60","author":"Lenfant","year":"2021","journal-title":"Rheumatology"},{"key":"2025082723521313000_15.3.e247276.16","doi-asserted-by":"crossref","first-page":"756","DOI":"10.15585\/mmwr.mm6703a5","article-title":"Recommendations of the Advisory Committee on immunization practices for use of herpes zoster vaccines","volume":"67","author":"Dooling","year":"2018","journal-title":"MMWR Morb Mortal Wkly Rep"}],"container-title":["BMJ Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bcr-2021-247276","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,28]],"date-time":"2025-08-28T06:52:24Z","timestamp":1756363944000},"score":1,"resource":{"primary":{"URL":"https:\/\/casereports.bmj.com\/lookup\/doi\/10.1136\/bcr-2021-247276"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3]]},"references-count":16,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2022,3,2]]},"published-print":{"date-parts":[[2022,3]]}},"alternative-id":["10.1136\/bcr-2021-247276"],"URL":"https:\/\/doi.org\/10.1136\/bcr-2021-247276","relation":{},"ISSN":["1757-790X"],"issn-type":[{"value":"1757-790X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3]]}}}